李會榮 崔昭 梁博
[摘要] 目的 探討潰瘍性結腸炎(UC)患者腸道菌群含量變化及其與炎性因子及TOLL樣受體(TLRs)分子的相關性。 方法 選取2016年2月~2018年8月河北省保定市第二醫(yī)院收治的UC患者82例作為觀察組,另選取同期行健康體檢的志愿者70例作為對照組,檢測白細胞介素(IL)-4(IL-4)、IL-6、腫瘤壞死因子-α(TNF-α)、腸道菌群含量情況以及TLRs分子(TLR4、TLR9)表達情況并進行比較,采用Pearson相關性分析TLRs分子表達與腸道菌群、炎性因子的相關性。 結果 觀察組腸桿菌、擬桿菌、腸球菌以及梭桿菌含量高于對照組,而乳桿菌、雙歧桿菌含量則低于對照組,差異均有統(tǒng)計學意義(均P < 0.05)。觀察組TLR4、TLR9、IL-6、TNF-α高于對照組,IL-4低于對照組,差異均有統(tǒng)計學意義(均P < 0.05)。Pearson相關性分析結果顯示,UC患者TLR4、TLR9與腸桿菌、擬桿菌、腸球菌、梭桿菌、IL-6、TNF-α呈正相關(r > 0,P < 0.05),與乳桿菌、雙歧桿菌、IL-4呈負相關(r < 0,P < 0.05)。結論 UC患者體內腸道菌群失調,其可通過促進TLRs分子表達進而提高促炎因子水平,降低抑炎因子水平,介導腸黏膜炎性反應。
[關鍵詞] 潰瘍性結腸炎;腸道菌群;炎性因子;TOLL樣受體;相關性
[中圖分類號] R574.62 ? ? ? ? ?[文獻標識碼] A ? ? ? ? ?[文章編號] 1673-7210(2020)07(a)-0156-04
[Abstract] Objective To investigate the changes of intestinal flora in patients with ulcerative colitis (UC) and its correlation with inflammatory factors and TOLL-like receptors (TLRs) molecules. Methods A total of 82 patients with UC admitted to the NO.2 Hospital of Baoding Hebei Province from February 2016 to August 2018 were selected as the observation group, and 70 volunteers who underwent physical examination during the same period were selected as the control group. The levels of interleukin (IL)-4, IL-6, tumor necrosis factor-α (TNF-α), intestinal flora content and the expression of TLRs molecules (TLR4 and TLR9) were detected and compared. Pearson correlation was used to analyze the correlation between TLRs expression and intestinal flora and inflammatory factors. Results The contents of Enterobacter, Bacteroides, Enterococcus and Fusobacterium in the observation group were higher than those in the control group, while the contents of Lactobacillus and Bifidobacterium in the observation group were lower than those in the control group, with statistically significant differences (all P < 0.05). TLR4, TLR9, IL-6 and TNF-α in the observation group were higher than those in the control group, and IL-4 was lower than that in the control group, with statistically significant differences (all P < 0.05). Pearson correlation analysis showed that TLR4 and TLR9 in UC patients were positively correlated with Enterobacter, Bacteroides, Enterococcus, Fusobacterium, IL-6 and TNF-α (r > 0,P < 0.05), but negatively correlated with Lactobacillus, Bifidobacterium and IL-4 (r < 0,P < 0.05). Conclusion In patients with UC, intestinal flora is dysregulated, which can promote the expression of TLRs molecules to increase the level of pro-inflammatory factors, reduce the level of anti-inflammatory factors, and mediate the inflammatory response of intestinal mucosa.
TOLL基因最早于果蠅體內發(fā)現(xiàn),其編碼的跨膜受體蛋白稱TLR,TLR是一個新型的細胞受體蛋白家族,而TLRs則是體內重要的模式識別受體,具有識別多種病原菌的能力,通過下游髓樣分化因子88以促進核因子-κB進入細胞核,最終啟動多種炎性因子表達[14-15]。其中TLR4能識別脂多糖,同時能介導腸上皮細胞對細菌胞壁成分的反應,有研究表明,高TLR4水平可通過影響腸上皮細胞對細菌胞壁成分的信號傳遞,促進炎性因子的增殖,導致腸道炎性反應[16];TLR9能夠識別細菌的非甲基化的胞嘧啶-磷酸-鳥嘌呤基序,可介導胞嘧啶-磷酸-鳥嘌呤基序激活T細胞、DC細胞、B細胞等多種免疫細胞,誘導免疫應答,參與UC的發(fā)生發(fā)展[17]。本研究中觀察組TLR4、TLR9高于對照組,可見腸黏膜中的TLR4、TLR9參與UC的病情進展,與陳勝等[18]學者研究結果一致。進一步Pearson相關性分析結果提示,TLR4、TLR9與腸桿菌、擬桿菌、腸球菌、梭桿菌呈正相關,與乳桿菌、雙歧桿菌呈負相關,提示UC患者中腸道菌群紊亂可促進TLR4、TLR9高表達,與李順清等[15]研究結論相符。TNF-α是炎癥啟動因子,參與著炎癥的發(fā)生發(fā)展過程[19]。IL-4為抑炎因子,可下調炎癥細胞因子基因的轉錄及其分泌,發(fā)揮抗炎和免疫調節(jié)作用,是腸道免疫的重要因子[20]。IL-6是一種促炎細胞因子,可加劇腸黏膜炎性反應[21]。本研究中觀察組IL-6、TNF-α均高于對照組,IL-4低于對照組,可見IL-6、TNF-α、IL-4均參與著UC的病情進展過程,同時相關性分析也顯示TLR4、TLR9與IL-6、TNF-α呈正相關,與IL-4呈負相關,說明腸黏膜中的TLR4、TLR9可能通過識別腸道內異常繁殖的腸桿菌、腸球菌等條件致病菌及擬桿菌、梭桿菌等病原菌調控IL-6、TNF-α、IL-4水平進而介導炎性反應[22-25]。
綜上所述,UC患者體內腸道菌群失調,其可通過促進TLRs分子表達進而提高促炎因子水平,降低抑炎因子水平,介導腸黏膜炎性反應。
[參考文獻]
[1] ?Ungaro R,Mehandru S,Allen PB,et al. Ulcerative colitis [J]. Lancet,2017,389(10080):1756-1770.
[2] ?李世權,呂曉丹,謝彥飛,等.潰瘍性結腸炎小鼠外周血和結腸組織中Tfh、Tfr細胞水平變化及意義[J].山東醫(yī)藥,2018,58(9):9-12.
[3] ?施煜燕,周建波.老年潰瘍性結腸炎患者炎癥細胞因子、T淋巴細胞亞群和凝血功能變化[J].中國老年學雜志,2018,38(2):382-384.
[4] ?Adams SM,Bornemann PH. Ulcerative colitis [J]. Am Fam Physician,2013,87(10):699-705.
[5] ?楊斐,鄭曉娟,劉近春,等.潰瘍性結腸炎腸道菌群失調的治療進展[J].胃腸病學,2018,23(1):56-58.
[6] ?Ordás I,Eckmann L,Talamini M,et al. Ulcerative colitis [J]. Lancet,2012,380(9853):1606-1619.
[7] ?中華醫(yī)學會消化病學分會炎癥性腸病學組.炎癥性腸病診斷與治療的共識意見(2012年·廣州)[J].中華內科雜志,2012,51(10):818-831.
[8] ?Cross R,Ko CW,Singh S. Mild-to-Moderate Ulcerative Colitis Guideline [J]. Gastroenterology,2019,156(3):768.
[9] ?王曉宏,張邑.槐花散聯(lián)合仙方活命飲治療潰瘍性結腸炎臨床研究[J].國際中醫(yī)中藥雜志,2017,39(8):701-704.
[10] ?Fukuda T,Naganuma M,Kanai T. Current new challenges in the management of ulcerative colitis [J]. Intest Res,2019,17(1):36-44.
[11] ?張永利,申妮.潰瘍性結腸炎患者腸道菌群的變化特征[J].河北醫(yī)藥,2018,40(7):1054-1057.
[12] ?劉志威,王學群,李甜甜,等.潰瘍性結腸炎患者腸道菌群變化的臨床意義[J].胃腸病學和肝病學雜志,2016, 25(5):554-556.
[13] ?李靜,陳衛(wèi)剛.腸道菌群治療潰瘍性結腸炎的研究進展[J].實用醫(yī)學雜志,2017,33(24):4189-4192.
[14] ?譚芳.益生菌對潰瘍性結腸炎大鼠腸黏膜TLRs表達的影響[D].烏魯木齊:新疆醫(yī)科大學,2015.
[15] ?李順清.潰瘍性結腸炎患者腸道菌群含量以及細胞因子、TLRs分子表達情況的檢測[J].海南醫(yī)學院學報,2017, 23(5):662-664,668.
[16] ?徐曉云,李冬斌,李彬.TLR4、NF-κB p65、IL-8在潰瘍性結腸炎中的表達[J].疑難病雜志,2012,11(3):181-183,封3.
[17] ?何雁,王啟之.Toll樣受體9與潰瘍性結腸炎[J].安徽醫(yī)藥,2009,13(6):593-595.
[18] ?陳勝,鄒開芳,楊天,等.Toll樣受體(TLR)2、TLR4和TLR9在大鼠結腸炎模型結腸組織中的表達及其意義[J].胃腸病學,2007,12(6):339-343.
[19] ?Panés J,Alfaro I. New treatment strategies for ulcerative colitis [J]. Expert Rev Clin Immunol,2017,13(10):963-973.
[20] ?岳文杰,劉懿,徐薇,等.潰瘍性結腸炎(UC)腸黏膜中IL-2、IL-4、IL-17和IL-10的表達特點及其與疾病活動度的關系[J].復旦學報:醫(yī)學版,2012,39(5):454-459,488.
[21] ?黃鶴,倫偉健,梁曉燕,等.沙利度胺對潰瘍性結腸炎大鼠MMP-9、COX-2、IL-6水平的影響[J].中國老年學雜志,2016,36(7):1594-1596.
[22] ?張愛軍,朱葉珊,費亞軍等.中藥封包電磁波導入輔治潰瘍性結腸炎的療效及對血清炎性因子和免疫球蛋白的影響[J].疑難病雜志,2018,17(4):370-373.
[23] ?鄧臺燕,全大祥,吳彬,等.復方黃柏液聯(lián)合美沙拉嗪對潰瘍性結腸炎及腸道菌群和血清炎癥因子的影響[J].中國現(xiàn)代醫(yī)學雜志,2016,26(9):124-127.
[24] ?王云濱,陳霞.益生菌聯(lián)合美沙拉嗪對潰瘍性結腸炎患者血清炎癥因子及免疫功能的影響[J].中國現(xiàn)代醫(yī)生,2020,58(9):40-43.
[25] ?李琳,鐘青.潰瘍性結腸炎患者腸道菌群變化與細胞因子、TLRs分子表達的相關性研究[J].傳染病信息,2017, 30(6):361-364.
(收稿日期:2019-07-30)